In 2014, the World Health Organization was notified of an outbreak of a communicable disease characterized by fever, severe diarrhea, vomiting, and a high fatality rate in Guinea. Virologic investigation identified Za...In 2014, the World Health Organization was notified of an outbreak of a communicable disease characterized by fever, severe diarrhea, vomiting, and a high fatality rate in Guinea. Virologic investigation identified Zaire ebolavirus (EBOV) as the causative agent. Approximately 30 years after the first epidemic, there is no vaccine or therapeutic medication approved to counter the Ebola virus. In this review, it emphasized that plant based antibodies can be an effective cure to Ebola hemorrhagic fever. Genetically modified Nicotiana benthamiana is used to manufacture ZMapp drug by Kentucky BioProcessing. ZMapp three-antibody cocktail binds to the Ebola virus to deactivate it and provides simulated immune response against sugar-tagged proteins on the outside of the Ebola virus, which had verified efficacy against Ebola infection in nonhuman primates and also successfully treated two American medical workers infected with Ebola virus disease.展开更多
Ebola virus disease(EVD)is a life-threatening viral disease with a fatality rate ranging from around 30%to 90%.The first EVD outbreak was reported in the 1970s in Zaire(now the Democratic Republic of the Congo).Until ...Ebola virus disease(EVD)is a life-threatening viral disease with a fatality rate ranging from around 30%to 90%.The first EVD outbreak was reported in the 1970s in Zaire(now the Democratic Republic of the Congo).Until 2013,most outbreaks occurred in the Central Africa region,including Zaire,Sudan and Uganda.However,between March and October 2014,over 10000 cases of EVD have been recorded in West Africa,such as in Guinea,Liberia,Sierra Leone,and Nigeria,and a few hospital or secondary infections of EVD have occurred in Spain and the United States of America.EVD is presently one of the world's most feared diseases.In this literature review,we describe the epidemiology,clinical features,diagnosis,and treatment of EVD.展开更多
文摘In 2014, the World Health Organization was notified of an outbreak of a communicable disease characterized by fever, severe diarrhea, vomiting, and a high fatality rate in Guinea. Virologic investigation identified Zaire ebolavirus (EBOV) as the causative agent. Approximately 30 years after the first epidemic, there is no vaccine or therapeutic medication approved to counter the Ebola virus. In this review, it emphasized that plant based antibodies can be an effective cure to Ebola hemorrhagic fever. Genetically modified Nicotiana benthamiana is used to manufacture ZMapp drug by Kentucky BioProcessing. ZMapp three-antibody cocktail binds to the Ebola virus to deactivate it and provides simulated immune response against sugar-tagged proteins on the outside of the Ebola virus, which had verified efficacy against Ebola infection in nonhuman primates and also successfully treated two American medical workers infected with Ebola virus disease.
文摘Ebola virus disease(EVD)is a life-threatening viral disease with a fatality rate ranging from around 30%to 90%.The first EVD outbreak was reported in the 1970s in Zaire(now the Democratic Republic of the Congo).Until 2013,most outbreaks occurred in the Central Africa region,including Zaire,Sudan and Uganda.However,between March and October 2014,over 10000 cases of EVD have been recorded in West Africa,such as in Guinea,Liberia,Sierra Leone,and Nigeria,and a few hospital or secondary infections of EVD have occurred in Spain and the United States of America.EVD is presently one of the world's most feared diseases.In this literature review,we describe the epidemiology,clinical features,diagnosis,and treatment of EVD.
